Quoin Pharmaceuticals Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment The late-stage specialty pharmaceutical company developing treatments for rare and orphan diseases Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), announced a robust

#QNRX Reports Strong Q1 Progress with Breakthroughs in Netherton Syndrome Treatment
#NethertonSyndrome #QuoinPharmaceuticals
prismmarketview.com/quoin-pharma...